Delivery Order SPE2DB24D2003-SPE2DB25FXLQ2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $15,422.40 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 0.5 mg on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract requires delivery to AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $9,482.33. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 1, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $4,508.41 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count package) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's extensive pharmaceutical distribution portfolio for federal medical procurement. The product will be...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count packages) valued at $14,929.95 with a firm fixed price structure. This delivery order represents a competitive award with no set-aside designation and is set to conclude by August 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work from its Corporate Office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,697.80 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $23,256.95 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. This non-set-aside award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a pharmaceutical delivery to support federal medical procurement needs. The contract is executed from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $74,612.17. This non-competitive delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $5,458.34 to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 2 mg on September 11, 2025, with completion scheduled for September 12, 2025. This firm fixed-price, non-set-aside contract represents a pharmaceutical supply delivery executed through AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLQ2Delivery Order
The Defense Logistics Agency awarded a $4,729.87 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 1 mg on August 12, 2025, with completion scheduled for August 13, 2025. This competitive award utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply agreement running through December 2026. The parent IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, medical devices, and specialized healthcare commodities to military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare customers. Rexulti (brexpiprazole) is a psychiatric medication used in treating major depressive disorder and schizophrenia, reflecting the therapeutic range of products delivered under this strategic pharmaceutical prime vendor arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/12/25 |